Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies

Andres Forero-Torres, Nancy L. Bartlett, Robert B. Berryman, Robert Chen, Jeffrey V. Matous, Michelle A. Fanale, Owen A. O'Connor, Randal Olshefski, Scott E. Smith, Dirk Huebner, Pamela L. Levine, Laurie E. Grove, Ajay K. Gopal

Research output: Contribution to journalArticle

9 Scopus citations
Original languageEnglish
Pages (from-to)1151-1153
Number of pages3
JournalLeukemia and Lymphoma
Volume56
Issue number4
DOIs
StatePublished - Apr 1 2015

Cite this

Forero-Torres, A., Bartlett, N. L., Berryman, R. B., Chen, R., Matous, J. V., Fanale, M. A., O'Connor, O. A., Olshefski, R., Smith, S. E., Huebner, D., Levine, P. L., Grove, L. E., & Gopal, A. K. (2015). Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies. Leukemia and Lymphoma, 56(4), 1151-1153. https://doi.org/10.3109/10428194.2014.951843